Compare Opendoor Technologies Inc (OPEN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Opendoor Technologies Inc vs ResMed Inc. — how do they compare? Opendoor Technologies Inc trades at $2.22 (market cap $2.22B), while ResMed Inc. trades at $228.81 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 14.4× Opendoor Technologies Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Opendoor Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Opendoor Technologies Inc for 33 Days and ResMed Inc. for 51 Days on average.
| OPEN | RMD | |
|---|---|---|
Market Cap | $2.22B | $31.89B |
Volume | 28,705,892 | 618,314 |
Sector | Real Estate | Health |
52-Week High | $9.37 | $277.88 |
52-Week Low | $2.27 | $182.82 |
Typical Hold Time | 33 Days | 51 Days |
Enterprise Value | $3.29B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Opendoor Technologies (OPEN) trades at $2.215, down 2.42% on the day, reflecting ongoing challenges in the iBuying sector. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentals reveal significant losses with a -46.74% net income margin and -$1.3B net loss in 2025. Recent news highlights mortgage expansion efforts and housing market sensitivity to interest rate fluctuations, with the company aiming for adjusted net income breakeven at a $9B revenue run rate.
Despite trading near analyst consensus price target of $4.92 (122% upside), OPEN faces substantial execution risks amid persistent losses and high debt levels. The bullish case relies on successful mortgage expansion and housing market recovery, but current financial metrics and technical indicators suggest continued volatility. Investors should weigh the significant discount to analyst targets against the company's challenging path to profitability.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
